Latest Breaking News On - Jan davidson moncada - Page 1 : vimarsana.com

WU-CART-007 Receives FDA RMAT and EMA PRIME Designations for R/R T-ALL and T-LBL

WU-CART-007 has received RMAT and PRIME designations in relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting

Wugen, Inc.: Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress

-- WU-CART-007 was well-tolerated in patients with R/R T-ALL/LBL, with low incidence of high-grade CRS and immune-related adverse events -- -- WU-CART-007 demonstrated preliminary evidence of anti-leukemic

Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced Colorectal Cancer (CRC) at ASCO Gastrointestinal Cancers Symposium

Wugen Presents Data Supporting Clinical Development of WU-NK-101 for Relapsed / Refractory AML at th

– Genetic tumor microenvironment (TME) signature identified as highly predictive of duration of response to cytokine-induced memory-like (CIML) NK cell therapy –– WU-NK-101 exhibited enhanced anti-tumor activity, robust bone marrow trafficking, and metabolic flexibility –– Phase 1 clinical study of WU-NK-101 for off...

Wugen, Inc.: Wugen Presents New Preclinical Data Demonstrating Enhanced Anti-Tumor Activity of WU-NK-101 at the European Hematology Association (EHA) 2022 Hybrid Congress

-- WU-NK-101 exhibited enhanced metabolic flexibility and resistance to tumor microenvironment (TME) immunosuppression relative to conventional natural killer (NK) cells -- -- WU-NK-101 demonstrated

Wugen, Inc.: Wugen to Present Preclinical Data on WU-NK-101 at the European Hematology Association (EHA) 2022 Hybrid Congress

Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced it will